Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies.

Archive ouverte

Witkowski, Benoit | Amaratunga, Chanaki | Khim, Nimol | Sreng, Sokunthea | Chim, Pheaktra | Kim, Saorin | Lim, Pharath | Mao, Sivanna | Sopha, Chantha | Sam, Baramey | Anderson, Jennifer M | Duong, Socheat | Chuor, Char Meng | Taylor, Walter R J | Suon, Seila | Mercereau-Puijalon, Odile | Fairhurst, Rick M | Menard, Didier

Edité par CCSD ; New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001- -

International audience. BACKGROUND: Artemisinin resistance in Plasmodium falciparum lengthens parasite clearance half-life during artemisinin monotherapy or artemisinin-based combination therapy. Absence of in-vitro and ex-vivo correlates of artemisinin resistance hinders study of this phenotype. We aimed to assess whether an in-vitro ring-stage survival assay (RSA) can identify culture-adapted P falciparum isolates from patients with slow-clearing or fast-clearing infections, to investigate the stage-dependent susceptibility of parasites to dihydroartemisinin in the in-vitro RSA, and to assess whether an ex-vivo RSA can identify artemisinin-resistant P falciparum infections. METHODS: We culture-adapted parasites from patients with long and short parasite clearance half-lives from a study done in Pursat, Cambodia, in 2010 (registered with ClinicalTrials.gov, number NCT00341003) and used novel in-vitro survival assays to explore the stage-dependent susceptibility of slow-clearing and fast-clearing parasites to dihydroartemisinin. In 2012, we implemented the RSA in prospective parasite clearance studies in Pursat, Preah Vihear, and Ratanakiri, Cambodia (NCT01736319), to measure the ex-vivo responses of parasites from patients with malaria. Continuous variables were compared with the Mann-Whitney U test. Correlations were analysed with the Spearman correlation test. FINDINGS: In-vitro survival rates of culture-adapted parasites from 13 slow-clearing and 13 fast-clearing infections differed significantly when assays were done on 0-3 h ring-stage parasites (10*88% vs 0*23%; p=0*007). Ex-vivo survival rates significantly correlated with in-vivo parasite clearance half-lives (n=30, r=0*74, 95% CI 0*50-0*87; p<0*0001). INTERPRETATION: The in-vitro RSA of 0-3 h ring-stage parasites provides a platform for the molecular characterisation of artemisinin resistance. The ex-vivo RSA can be easily implemented where surveillance for artemisinin resistance is needed. FUNDING: Institut Pasteur du Cambodge and the Intramural Research Program, NIAID, NIH.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion